Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISE™(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice

NCT01426230 is registered in ClinicalTrials.gov with Depomed as lead sponsor.

NCT NCT01426230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01426230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISE™(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice
Lead sponsor
Depomed
Phase
Observational
Overall status
Completed
Start date
September 30, 2011
Completion date
April 30, 2012
Enrollment
201 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

post herpetic neuralgia